The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England
by
Biswas PN, Wilton LV, Shakir SA.
Drug Safety Research Unit, Bursledon Hall,
Southampton, London, UK.
pipasha.biswas@dsru.org
J Psychopharmacol. 2003 Mar;17(1):121-6.

ABSTRACT

Mirtazpine is the first noradrenaline and serotonin specific antidepressant. We monitored the safety of mirtazapine as reported in primary practice in England.The exposure data were provided by monitoring the dispensed prescriptions issued between September 1997 and February 1999. Questionnaires sent to GPs provided outcome data. Drowsiness/sedation and malaise/lassitude were the most frequent ADRs (116, 71 respectively) and had the highest incidence density (per 1000 patient-months) in the first month of treatment (58.1, 27.8 respectively). Agitation (73), aggression (70), rash (20), hallucinations (13) and abnormal dreams (31 were unlabelled AES while abnormal liver function tests (12), syncope (8), abnormal behaviour (4) and visual disturbance (3) were labelled AES possibly due to mirtazapine use. Serious suspected ADRs reported were facial oedema (5), allergy (3), bone marrow toxicity (2) and myelodysplasia (1).

Options
Mirtazapine
Mirtazapine v SSRIs
Mirtazapine and sleep
Mirtazapine : overview
Mirtazapine v paroxetine
Mirtazapine v imipramine
Mirtazapine v venlafaxine
Mirtazapine and depression
Antidepressant mechanisms
Mirtazapine and the receptors
Mirtazapine and sexual behaviour
Mirtazapine-induced dysphoric mania
Mirtazapine (Remeron) during pregnancy
Mirtazapine (Remeron): pharmacokinetics
Mirtazapine as an antidepressant: safety and efficacy
Mirtazapine (Remeron)-induced spontaneous orgasms

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family